BioSuperior™ Anti-CD47 Therapeutic Antibody (AVI-105)
MILPITAS, Calif., May 13, 2020 – AbVision, Inc., an innovative biopharmaceutical company, announced today that the Company has developed a biosuperior anti-CD47 therapeutic antibody (AVI-105), powered by its SpeedyAb™ technology platform of therapeutic antibody.
CD47 is a “don’t eat me” signal that is over expressed on cancer cells and enables cancer cells to escape macrophage phagocytosis. Blocking of CD47 significantly enables tumor cell phagocytosis and activates an ant-tumor T cell response. Anti-CD47 clinical candidates are being evaluated as an anti-cancer therapy both as a mono and combination therapy with good efficacy and safety profiles. Recent data also showed that blockade of CD47 inhibitory signaling greatly enhances innate and adaptive immune responses against viral infection.
AbVision’s newly developed AVI-105, the biosuperior anti-CD47 therapeutic antibody, shows similar or better preclinical results in comparison to a reference antibody in the clinical trial stage (Magrolimab, Hu5F9-G4). In a parallel comparison to the reference antibody, AVI-105 showed comparable binding affinity to its targets, comparable neutralizing activity in receptor-ligand blockade studies, and comparable anti-tumor activity in animal studies (Fig. 1).
Fig. 1. AVI-105.2 showed strong anti-tumor activity in vivo studies.
However, AVI-105 demonstrated more potent macrophage-mediated phagocytosis than its reference antibody (Fig. 2). In addition, more significantly, AVI-105 induced less hemagglutination (Fig. 3), indicating the biosuperior anti-CD47 antibody may generate minimized level of toxicity in vivo in comparison to the toxicity level from its reference antibody. The Company has now successfully completed a series of preclinical studies and further proceed the project to the IND-enabling stage. AVI-105 antibody candidate is available for out-licensing and collaborations for downstream development and clinical studies, according to the Company.
Fig.2. AVI-105 elicited more potent macrophage-mediated phagocytosis than its reference antibody.
Fig. 3. AVI-105 induced less hemagglutination than its reference antibody.
About AbVision Inc.
AbVision, Inc. is a biopharmaceutical company with its R&D center in the SF Bay Area. The Company focuses on discovery and development of therapeutic antibodies, vaccines and cell therapy. The Company’s innovative technology platforms provide distinct advantages for antibody discovery, vaccine development and cancer therapies. AbVision aims to use the novel SpeedyAb™, ImmunoBusterTM, TsKill™ technology platforms for generating next generation of bio-therapeutics in cancer therapy and infectious diseases. Several other monoclonal antibodies for cancer therapies and vaccine candidates are also available for out-licensing to enable faster downstream development and clinical studies. Please see AbVision website (http://abvisioninc.com/) for the details.
About SpeedyAb™
AbVision’s SpeedyAb™ Technology platform provides high-throughput features of antibody screening for obtaining the therapeutic leads with high affinity and broad diversity.
For Licensing and Collaborations
Contact AbVision’s Business Development and Licensing Department (BD&L) by email licensing@abvisioninc.com or phone +1-408-493-1822. For more information about AbVision, visit www.abvisioninc.com.
First-In-Class Active Targeting Vaccine Candidate for COVID-19
MILPITAS, Calif., May 1, 2020 – AbVision, Inc., an innovative biopharmaceutical company, announced today that the Company has developed a novel first-in-class COVID-19 vaccine candidate (AVI-205) with an active targeting feature, powered by its ImmunoBuster-IITM Active Targeting Vaccine Platform.
This novel COVID-19 vaccine candidate actively targets immune cells upon injection, as compared to the passive diffusion mechanism of traditional vaccines, resulting in quickly generation of potent neutralizing IgG antibodies that block the binding of SARS-CoV-2 S1 to hACE2 in less than one week, an immune response that usually takes more than two weeks to achieve with other vaccines. The Active Targeting COVID-19 vaccine candidate is more potent than vaccines without the active targeting feature, eliciting both a more rapid immune response and a greater resultant IgG antibody titer (see Fig. 1 and Fig. 2).
The Company has now successfully completed preclinical studies and generated promising data. As a result, this novel COVID-19 vaccine candidate is now available for out-licensing and collaborations for downstream development and clinical studies, according to the Company.
Figure 1. Generation of Anti-SARS-CoV-2 Spike Protein IgG Antibodies. SARS-CoV-2 S1 specific IgG was measured following vaccination in mice with Active Targeting COVID-19 Vaccine (AVI-205). Rapid and robust immune response was observed in less than a week.
Figure 2. ELISA-Based Receptor-Binding Inhibition Assay. Specific SARS-CoV-2 S1-hACE2 binding was inhibited in vitro using serum collected from mice vaccinated with Active Targeting COVID-19 Vaccine (AVI-205). The inhibition of S1-hACE2 binding was observed in as early as 6 days post vaccination.
About AbVision
AbVision, Inc. is a biopharmaceutical company with its R&D center in the SF Bay Area. The Company focuses on discovery and development of therapeutic antibodies and vaccines. The Company’s innovative technology platforms provide distinct advantages for antibody discovery, vaccine development and cancer therapies. AbVision aims to use the novel ImmunoBuster-IITM Active Targeting Vaccine Platform to develop more powerful vaccines with faster, stronger immune responses for prophylactic and therapeutic treatments. Several other Active Targeting vaccines including a human rabies vaccine as well as several monoclonal antibodies for cancer therapies are also available for out-licensing to enable faster downstream development and clinical studies.
About ImmunoBuster-IITM
AbVision’s ImmunoBuster-IITM Active Targeting Vaccine Platform is a first-in-class potent immune activator with targeting feature, created on top of the innovation of the Company’s renowned ImmunoBuster-ITM technology. Vaccines powered by ImmunoBuster-IITM can elicit robust isotype switched IgG response in less than a week and maintain long-lasting IgG response post vaccination. ImmunoBuster-IITM can work synergistically with essentially all commercially available vaccines to elicit faster and stronger neutralizing immunity than current vaccinations.
For Licensing and Collaborations
Contact AbVision’s Business Development and Licensing Department (BD&L) by email licensing@abvisioninc.com or phone +1-408-493-1822. For more information about AbVision, visit www.abvisioninc.com.